Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2016 4
2017 2
2018 1
2019 1
2020 2
2021 2
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
The ex vivo pharmacology of HIV-1 antiretrovirals differs between macaques and humans.
Herrera C, Cottrell ML, Prybylski J, Kashuba ADM, Veazey RS, García-Pérez J, Olejniczak N, McCoy CF, Ziprin P, Richardson-Harman N, Alcami J, Malcolm KR, Shattock RJ. Herrera C, et al. Among authors: olejniczak n. iScience. 2022 May 16;25(6):104409. doi: 10.1016/j.isci.2022.104409. eCollection 2022 Jun 17. iScience. 2022. PMID: 35663021 Free PMC article.
Epigenetic Features of HIV-Induced T-Cell Exhaustion Persist Despite Early Antiretroviral Therapy.
Martin GE, Sen DR, Pace M, Robinson N, Meyerowitz J, Adland E, Thornhill JP, Jones M, Ogbe A, Parolini L, Olejniczak N, Zacharopoulou P, Brown H, Willberg CB, Nwokolo N, Fox J, Fidler S, Haining WN, Frater J. Martin GE, et al. Among authors: olejniczak n. Front Immunol. 2021 Jun 4;12:647688. doi: 10.3389/fimmu.2021.647688. eCollection 2021. Front Immunol. 2021. PMID: 34149690 Free PMC article. Clinical Trial.
Impact of antiretroviral therapy in primary HIV infection on natural killer cell function and the association with viral rebound and HIV DNA following treatment interruption.
Pace M, Ogbe A, Hurst J, Robinson N, Meyerowitz J, Olejniczak N, Thornhill JP, Jones M, Waters A, Lwanga J, Kuldanek K, Hall R, Zacharopoulou P, Martin GE, Brown H, Nwokolo N, Peppa D, Fox J, Fidler S, Frater J. Pace M, et al. Among authors: olejniczak n. Front Immunol. 2022 Aug 30;13:878743. doi: 10.3389/fimmu.2022.878743. eCollection 2022. Front Immunol. 2022. PMID: 36110857 Free PMC article.
Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8+ T cell antiviral responses.
Yang H, Llano A, Cedeño S, von Delft A, Corcuera A, Gillespie GM, Knox A, Leneghan DB, Frater J, Stöhr W, Fidler S, Mothe B, Mak J, Brander C, Ternette N, Dorrell L; Research in Viral Eradication of Reservoirs (RIVER) trial study group. Yang H, et al. Cell Rep. 2021 May 11;35(6):109103. doi: 10.1016/j.celrep.2021.109103. Cell Rep. 2021. PMID: 33979627 Free article.
CD32-Expressing CD4 T Cells Are Phenotypically Diverse and Can Contain Proviral HIV DNA.
Martin GE, Pace M, Thornhill JP, Phetsouphanh C, Meyerowitz J, Gossez M, Brown H, Olejniczak N, Lwanga J, Ramjee G, Kaleebu P, Porter K, Willberg CB, Klenerman P, Nwokolo N, Fox J, Fidler S, Frater J. Martin GE, et al. Among authors: olejniczak n. Front Immunol. 2018 May 4;9:928. doi: 10.3389/fimmu.2018.00928. eCollection 2018. Front Immunol. 2018. PMID: 29780387 Free PMC article.
Levels of Human Immunodeficiency Virus DNA Are Determined Before ART Initiation and Linked to CD8 T-Cell Activation and Memory Expansion.
Martin GE, Pace M, Shearer FM, Zilber E, Hurst J, Meyerowitz J, Thornhill JP, Lwanga J, Brown H, Robinson N, Hopkins E, Olejniczak N, Nwokolo N, Fox J, Fidler S, Willberg CB, Frater J. Martin GE, et al. Among authors: olejniczak n. J Infect Dis. 2020 Mar 16;221(7):1135-1145. doi: 10.1093/infdis/jiz563. J Infect Dis. 2020. PMID: 31776569 Free PMC article.
Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis.
Fox J, Tiraboschi JM, Herrera C, Else L, Egan D, Dickinson L, Jackson A, Olejniczak N, Back D, Khoo S, Shattock R, Boffito M. Fox J, et al. Among authors: olejniczak n. J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):252-257. doi: 10.1097/QAI.0000000000001108. J Acquir Immune Defic Syndr. 2016. PMID: 27727157 Clinical Trial.
Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial.
Fidler S, Stöhr W, Pace M, Dorrell L, Lever A, Pett S, Kinloch-de Loes S, Fox J, Clarke A, Nelson M, Thornhill J, Khan M, Fun A, Bandara M, Kelly D, Kopycinski J, Hanke T, Yang H, Bennett R, Johnson M, Howell B, Barnard R, Wu G, Kaye S, Wills M, Babiker A, Frater J; RIVER trial study group. Fidler S, et al. Lancet. 2020 Mar 14;395(10227):888-898. doi: 10.1016/S0140-6736(19)32990-3. Epub 2020 Feb 19. Lancet. 2020. PMID: 32085823 Clinical Trial.
15 results